Where Innovations Meets Personalized and Precision Medicine
Keywords = Drug Development
Number of Articles: 2
Pharmacogenomics: Unlocking the Future of Personalized Medicine and Precision Drug Development

Pharmacogenomics: Unlocking the Future of Personalized Medicine and Precision Drug Development

Volume 10, Issue 37, Spring 2025, Pages 39-47

https://doi.org/10.22034/pmj.2025.2049550.1050

Sanaz Khosravi Ghareh Cheh

Abstract Pharmacogenomics is a relatively new subject that utilizes genomics and pharmacology to investigate the ways in which genetic variants influence individual responses to treatment with pharmaceuticals. A departure from the conventional "one-size-fits-all" treatment strategy is marked by the advent of pharmacogenomics, which makes it possible to tailor pharmacological regimens to the specific genetic profile of an individual. Significant improvements in pharmacological efficacy, reductions in adverse drug reactions (ADRs), and assistance in the development of drugs that are both safe and effective for a wide range of conditions are all possible outcomes of this domain. The purpose of this study is to investigate the prospective results of pharmacogenomics, with a particular emphasis on the function it plays in the process of drug development and its incorporation into personalized medicine. The purpose of this study is to investigate the genetic characteristics that influence the metabolism, efficacy, and toxicity of drugs, as well as to investigate the regulatory framework that is associated with pharmacogenomics testing. This paper provides a synopsis of the most important genes that are involved in pharmacogenomic responses, as well as a discussion of the potential difficulties that may arise in their practical use and the anticipated breakthroughs in this area of study.

Your Body on a Chip: Functional Testing for Personalized Medicine

Your Body on a Chip: Functional Testing for Personalized Medicine

Volume 7, Issue 27, Autumn 2022, Pages 1-7

https://doi.org/10.22034/pmj.2022.700885

Mona Aghassizadeh-Sherbaf, Jumi Bora, Aynaz Mazandarani

Abstract Despite the well-known high prevalence of failure in drug development, recent advancements in tissue engineering and microfabrication have helped to create microphysiological systems (MPS), or "organs-on-chips," which mimic the function of human organs. These "tissue chips" might be used for toxicity and drug screening tests, which could revolutionize the early phases of the drug development process. Additionally, they may be utilized to simulate disease conditions, supplying new instruments for deciphering disease pathologies and causes and evaluating the efficacy of novel treatments. Future clinical trials on chips might be utilized to assess novel medicines in both populations and individuals, opening the door for precision medicine. Here, we'll discuss tissue chips' diverse potential and the difficulties in developing them.